Scoring systems for the evaluation of adnexal masses nature: current knowledge and clinical applications

References

• Abdalla N, Piórkowski R, Stanirowski P, Cendrowski K, Sawicki W. 2017. Can replacing CA125 with HE4 in risk of malignancy indices 1–4 improve diagnostic performance in the presurgical assessment of adnexal tumors? BioMed Research International 2017:1–12.
   Web of Science ®Google Scholar
• Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. 2010. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pacific Journal of Cancer Prevention : APJCP 11:111–116.
   PubMed Web of Science ®Google Scholar
• Aktürk E, Karaca RE, Alanbay İ, Dede M, Karaşahin E, Yenen MC, Başer İ. 2011. Comparison of four malignancy risk indices in the detection of malignant ovarian masses. Journal of Gynecologic Oncology 22:177.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. 2002. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstetrics and Gynecology 100:1413–1416.
   PubMedGoogle Scholar
• American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology, 2016. Practice Bulletin No. 174: evaluation and management of adnexal masses. Obstetrics and Gynecology 128:e210–e226.
   PubMed Web of Science ®Google Scholar
• Andersen ES, Knudsen A, Rix P, Johansen B. 2003. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecologic Oncology 90:109–112.
   PubMed Web of Science ®Google Scholar
• Barra F, Laganà AS, Ghezzi F, Casarin J, Ferrero S. 2019. Nintedanib for advanced epithelial ovarian cancer: a change of perspective? Summary of evidence from a systematic review. Gynecologic and Obstetric Investigation 84:107–117.
   PubMed Web of Science ®Google Scholar
• Bellia A, Vitale SG, Laganà AS, Cannone F, Houvenaeghel G, Rua S, et al. 2016. Feasibility and surgical outcomes of conventional and robot-assisted laparoscopy for early-stage ovarian cancer: a retrospective, multicenter analysis. Archives of Gynecology and Obstetrics 294:615–622.
   PubMed Web of Science ®Google Scholar
• Bouzari Z, Yazdani S, Ahmadi MH, Barat S, Kelagar ZS, Kutenaie MJ, et al. 2011. Comparison of three malignancy risk indices and CA-125 in the preoperative evaluation of patients with pelvic masses. BMC Research Notes 4:206.
   PubMedGoogle Scholar
• Bristow RE, Smith A, Zhang Z, Chan DW, Crutcher G, Fung ET, Munroe DG. 2013. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecologic Oncology 128:252–259.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. 2002. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 20:1248–1259.
   PubMed Web of Science ®Google Scholar
• Chiofalo B, Laganà AS, Palmara V, Granese R, Corrado G, Mancini E, et al. 2017. Fasting as possible complementary approach for polycystic ovary syndrome: Hope or hype? Medical Hypotheses 105:1–3.
   PubMed Web of Science ®Google Scholar
• Cignini P, Vitale SG, Laganà AS, Biondi A, La Rosa VL, Cutillo G, 2017. Preoperative work-up for definition of lymph node risk involvement in early stage endometrial cancer: 5-year follow-up. Updates in Surgery 69:75–82.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, et al. 2016. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. American Journal of Obstetrics and Gynecology 215:82.e1–82.e11.
   PubMed Web of Science ®Google Scholar
• Curtin J. 1994. Management of the Adnexal Mass. Gynecologic Oncology 55:S42–S46.
   PubMed Web of Science ®Google Scholar
• Davies AP, Jacobs I, Woolas R, Fish A, Oram D. 1993. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. BJOG: An International Journal of Obstetrics and Gynaecology 100:927–931.
   Web of Science ®Google Scholar
• Dizon DS. 2017. PARP inhibitors for targeted treatment in ovarian cancer. The Lancet 390:1929–1930.
   PubMed Web of Science ®Google Scholar
• Dora SK, Dandapat AB, Pande B, Hota JP. 2017. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass. Journal of Ovarian Research 10:55.
   PubMed Web of Science ®Google Scholar
• El Bishry G, Tselos V, Pathi A. 2008. Correlation between laparoscopic and histological diagnosis in patients with endometriosis. Journal of Obstetrics and Gynaecology 28:511–515.
   Web of Science ®Google Scholar
• Epstein E, Van Calster B, Timmerman D, Nikman S. 2016. Subjective ultrasound assessment, the ADNEX model and ultrasound-guided tru-cut biopsy to differentiate disseminated primary ovarian cancer from metastatic non-ovarian cancer. Ultrasound in Obstetrics & Gynecology 47:110–116.
   PubMed Web of Science ®Google Scholar
• FDA Safety Communication. 2019. The FDA recommends against using screening tests for ovarian cancer screening [online]; [accessed 2019 Apr 15]. Available from: http://www.fda.gov/medicaldevices/safety/alerts and notices/ucm519413.htm
   Google Scholar
• Fung ET. 2010. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clinical Chemistry 56:327–329.
   PubMed Web of Science ®Google Scholar
• Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BWJ. 2009. The accuracy of risk scores in predicting ovarian malignancy. Obstetrics & Gynecology 113:384–394.
   PubMed Web of Science ®Google Scholar
• Ghisoni E, Katsaros D, Maggiorotto F, Aglietta M, Vaira M, De Simone M, et al. 2018. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. Journal of Ovarian Research 11:42.
   PubMed Web of Science ®Google Scholar
• Giampaolino P, Della Corte L, Foreste V, Vitale SG, Chiofalo B, Cianci S, et al. 2019. Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer. Minerva Medica 110:279–291.
   PubMed Web of Science ®Google Scholar
• Glanc P, Benacerraf B, Bourne T, Brown D, Coleman BG, Crum C, et al. 2017. First international consensus report on adnexal masses: management recommendations. Journal of Ultrasound in Medicine 36:849–863.
   PubMed Web of Science ®Google Scholar
• Goff BA, Agnew K, Neradilek MB, Gray HJ, Liao JB, Urban RR. 2017. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecologic Oncology 147:291–295.
   PubMed Web of Science ®Google Scholar
• Goodrich ST, Bristow RE, Santoso JT, Miller RW, Smith A, Zhang Z, Ueland FR. 2014. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. American Journal of Obstetrics and Gynecology 211:65.e1–65.e11.
   PubMed Web of Science ®Google Scholar
• Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, et al. 2018. Screening for ovarian cancer. JAMA 319:588.
   PubMed Web of Science ®Google Scholar
• Hayam F, Ashraf M, Hassan M. 2016. Assessment of the value of a modified risk of malignancy index (RMI) in preoperative discrimination between benign and malignant ovarian masses. Gynecology & Obstetrics 6.
   Google Scholar
• Høgdall E. 2016. Approaches to the detection of ovarian cancer. Scandinavian Journal of Clinical and Laboratory Investigation 76:S49–S53.
   PubMed Web of Science ®Google Scholar
• Holcomb K, Vucetic Z, Miller MC, Knapp RC. 2011. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. American Journal of Obstetrics and Gynecology 205:358.e1–358.e6.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. 1990. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology 97:922–929.
   Web of Science ®Google Scholar
• Javdekar R, Maitra N. 2015. Risk of malignancy index (RMI) in evaluation of adnexal mass. The Journal of Obstetrics and Gynecology of India 65:117–121.
   Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. 2014. Ovarian cancer. The Lancet 384:1376–1388.
   PubMed Web of Science ®Google Scholar
• Kaijser J, Sayasneh A, Van Hoorde K, Ghaem-Maghami S, Bourne T, Timmerman D, Van Calster B. 2014. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. Human Reproduction Update 20:449–462.
   PubMed Web of Science ®Google Scholar
• Karimi-Zarchi M, Mojaver SP, Rouhi M, Hekmatimoghaddam SH, Moghaddam RN, Yazdian-Anari P, Teimoori S. 2015. Diagnostic value of the risk of malignancy index (RMI) for detection of pelvic malignancies compared with pathology. Electronic Physician 7:1505–1510.
   PubMedGoogle Scholar
• Karlsen MA, Fagö-Olsen C, Høgdall E, Schnack TH, Christensen IJ, Nedergaard L, et al. 2016. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC–IV ovarian cancer—a part of the Danish prospective pelvic mass study. Tumor Biology 37:12619–12626.
   PubMedGoogle Scholar
• Karlsen MA, Høgdall EVS, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, et al. 2015. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer — An international multicenter study in women with an ovarian mass. Gynecologic Oncology 138:640–646.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Colonese F, Colonese E, Sofo V, Salmeri FM, Granese R, et al. 2015. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. European Journal of Gynaecological Oncology 36:495–505.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Rossetti P, Sapia F, Chiofalo B, Buscema M, Valenti G, et al. 2017. Evidence-based and patient-oriented inositol treatment in polycystic ovary syndrome: changing the perspective of the disease. International Journal of Endocrinology and Metabolism 15:e43695.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Sofo V, Vitale SG, Triolo O. 2016. Epithelial ovarian cancer inherent resistance: may the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role? Gynecologic Oncology Reports 18:57–58.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Vitale SG, Trovato MA, Palmara VI, Rapisarda AMC, Granese R, et al. 2016. Full-thickness excision versus shaving by laparoscopy for intestinal deep infiltrating endometriosis: rationale and potential treatment options. BioMed Research International 2016:3617179.
   PubMed Web of Science ®Google Scholar
• Lennox GK, Eiriksson LR, Reade CJ, Leung F, Mojtahedi G, Atenafu EG, et al. 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer. International Journal of Gynecological Cancer 25:809–814.
   PubMed Web of Science ®Google Scholar
• Longoria TC, Ueland FR, Zhang Z, Chan DW, Smith A, Fung ET, et al. 2014. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. American Journal of Obstetrics and Gynecology 210:78.e1–78.e9.
   PubMed Web of Science ®Google Scholar
• Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. 2013. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119:3454–3461.
   PubMed Web of Science ®Google Scholar
• Meys EMJ, Jeelof LS, Achten NMJ, Slangen BFM, Lambrechts S, Kruitwagen RFPM, Van Gorp T. 2017. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound in Obstetrics & Gynecology 49:784–792.
   PubMed Web of Science ®Google Scholar
• Meys EMJ, Kaijser J, Kruitwagen RFPM, Slangen BFM, Van Calster B, Aertgeerts B, et al. 2016. Subjective assessment versus ultrasound models to diagnose ovarian cancer: a systematic review and meta-analysis. European Journal of Cancer 58:17–29.
   PubMed Web of Science ®Google Scholar
• Moore RG, Blackman A, Miller MC, Robison K, DiSilvestro PA, Eklund EE, et al. 2019. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: can additional makers improve performance? Gynecologic Oncology 154:150–155.
   PubMed Web of Science ®Google Scholar
• Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. 2010. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. American Journal of Obstetrics and Gynecology 203:228.e1–228.e6.
   PubMed Web of Science ®Google Scholar
• Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC. 2012. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 118:91–100.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. n.d. SEER cancer statistics factsheets: ovary cancer. Bethesda (MD): National Cancer Institute.
   Google Scholar
• Naumann RW, Brown J. 2018. Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): good, bad, or just expensive? Gynecologic Oncology 149:117–120.
   PubMed Web of Science ®Google Scholar
• Nunes N, Yazbek J, Ambler G, Hoo W, Naftalin J, Jurkovic D. 2012. Prospective evaluation of the IOTA logistic regression model LR2 for the diagnosis of ovarian cancer. Ultrasound in Obstetrics & Gynecology 40:355–359.
   PubMed Web of Science ®Google Scholar
• Obeidat BR, Amarin ZO, Latimer JA, Crawford RA. 2004. Risk of malignancy index in the preoperative evaluation of pelvic masses. International Journal of Gynecology & Obstetrics 85:255–258.
   PubMed Web of Science ®Google Scholar
• Reyes-Muñoz E, Sathyapalan T, Rossetti P, Shah M, Long M, Buscema M, et al. 2018. Polycystic ovary syndrome: implication for drug metabolism on assisted reproductive techniques – a literature review. Advances in Therapy 35:1805–1815.
   PubMed Web of Science ®Google Scholar
• Rossetti D, Vitale SG, Gulino FA, Rapisarda AMC, Valenti G, Zigarelli M, et al. 2016. Laparoendoscopic single-site surgery for the assessment of peritoneal carcinomatosis resectability in patients with advanced ovarian cancer. European Journal of Gynaecological Oncology 37:671–673.
   PubMed Web of Science ®Google Scholar
• Rossetti D, Vitale SG, Tropea A, Biondi A, Laganà AS. 2017. New procedures for the identification of sentinel lymph node: shaping the horizon of future management in early stage uterine cervical cancer. Updates in Surgery 69:383–388.
   PubMed Web of Science ®Google Scholar
• Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ. 2010. SGO white paper on ovarian cancer: etiology, screening and surveillance. Gynecologic Oncology 119:7–17.
   PubMed Web of Science ®Google Scholar
• Schuurman MS, Kruitwagen RFPM, Portielje JEA, Roes EM, Lemmens VEPP, van der Aa MA. 2018. Treatment and outcome of elderly patients with advanced stage ovarian cancer: a nationwide analysis. Gynecologic Oncology 149:270–274.
   PubMed Web of Science ®Google Scholar
• Shibutani T, Takano M, Miyamoto M, Yoshikawa T, Aoyama T, Soyama H, et al. 2017. Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: a preliminary case series. Molecular and Clinical Oncology 7:51–55.
   PubMed Web of Science ®Google Scholar
• Shiozaki T, Miwa M, Sakuma T, Suzuki K, Kogiku A, Yamamoto K, et al. 2019. Correlation between pre-operative and final histological diagnosis on endometrial cancer. International Journal of Gynecologic Cancer 29:886–889.
   PubMed Web of Science ®Google Scholar
• Skates SJ. 2003. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. Journal of Clinical Oncology 21:206s–210s.
   PubMedGoogle Scholar
• Skates SJ. 2012. Ovarian cancer screening. International Journal of Gynecological Cancer 22:S24–S26.
   PubMed Web of Science ®Google Scholar
• Skates SJ, Pauler DK, Jacobs IJ. 2001. Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers. Journal of the American Statistical Association 96:429–439.
   Web of Science ®Google Scholar
• Terzic M, Dotlic J, Bila J, Pilic I, Nikolic B, Kocijancic D, et al. 2015. Utilization of ultrasound as a diagnostic tool in the preoperative assessment of patients with adnexal masses. Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology 20:862–869.
   PubMed Web of Science ®Google Scholar
• Terzic M, Dotlic J, Brndusic N, Arsenovic N, Likic I, Ladjevic N, et al. 2013a. Histopathological diagnoses of adnexal masses: which parameters are relevant in preoperative assessment? Ginekologia Polska 84:700–708.
   PubMed Web of Science ®Google Scholar
• Terzic M, Dotlic J, Likic I, Brndusic N, Pilic I, Ladjevic N, et al. 2013b. Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors. Taiwanese Journal of Obstetrics and Gynecology 52:253–257.
   PubMed Web of Science ®Google Scholar
• Terzic MM, Dotlic J, Likic I, Ladjevic N, Brndusic N, Arsenovic N, et al. 2013c. Current diagnostic approach to patients with adnexal masses: which tools are relevant in routine praxis? Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu 25:55–62.
   PubMed Web of Science ®Google Scholar
• Terzic M, Dotlic J, Likic I, Ladjevic N, Brndusic N, Mihailovic T, et al. 2013d. Predictive factors of malignancy in patients with adnexal masses. European Journal of Gynaecological Oncology 34:65–69.
   PubMed Web of Science ®Google Scholar
• Terzic M, Dotlic J, Likic I, Nikolic B, Brndusic N, Pilic I, et al. 2014. Diagnostic value of serum tumor markers evaluation for adnexal masses. Central European Journal of Medicine 9:210–216.
   Google Scholar
• Terzić M, Dotlić J, Ladjević IL, Atanacković J, Ladjević N. 2011. Evaluation of the risk malignancy index diagnostic value in patients with adnexal masses. Vojnosanitetski Pregled 68:589–593.
   PubMed Web of Science ®Google Scholar
• Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, et al. 2008. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound in Obstetrics and Gynecology 31:681–690.
   PubMed Web of Science ®Google Scholar
• Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. 1999. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstetrics & Gynecology 93:448–452.
   PubMed Web of Science ®Google Scholar
• Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, Nustad K. 1996. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. BJOG: An International Journal of Obstetrics and Gynaecology 103:826–831.
   Web of Science ®Google Scholar
• Ueland F. 2017. A perspective on ovarian cancer biomarkers: past, present and yet-to-come. Diagnostics 7:14.
   Web of Science ®Google Scholar
• Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, et al. 2011. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstetrics & Gynecology 117:1289–1297.
   PubMed Web of Science ®Google Scholar
• Ushijima K, Kawano K, Tsuda N, Nishio S, Terada A, Kato H, et al. 2015. Epithelial borderline ovarian tumor: diagnosis and treatment strategy. Obstetrics & Gynecology Science 58:183.
   PubMedGoogle Scholar
• Valenti G, Vitale SG, Tropea A, Biondi A, Laganà AS. 2017. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates in Surgery 69:441–449.
   PubMed Web of Science ®Google Scholar
• Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, et al. 2014. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: Prospective multicentre diagnostic study. BMJ 349:g5920.
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. 2011. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. British Journal of Cancer 104:863–870.
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Veldman J, Van Calster B, Cadron I, Leunen K, Amant F, et al. 2012. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer 48:1649–1656.
   PubMed Web of Science ®Google Scholar
• Van Holsbeke C, Van Calster B, Bourne T, Ajossa S, Testa AC, Guerriero S, et al. 2012. External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clinical Cancer Research 18:815–825.
   PubMed Web of Science ®Google Scholar
• Vitale SG, Capriglione S, Zito G, Lopez S, Gulino FA, Di Guardo F, et al. 2019. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Archives of Gynecology and Obstetrics 299:299–315.
   PubMed Web of Science ®Google Scholar
• Vitale SG, La Rosa VL, Rapisarda AMC, Laganà AS. 2017. The importance of fertility preservation counseling in patients with gynecologic cancer. Journal of Reproduction & Infertility 18:261–263.
   PubMedGoogle Scholar
• Vitale SG, La Rosa VL, Rapisarda AMC, Laganà AS. 2018. Fertility preservation in women with gynaecologic cancer: the impact on quality of life and psychological well-being. Human Fertility: Journal of the British Fertility Society 21:35–38.
   PubMed Web of Science ®Google Scholar
• Vitale SG, Marilli I, Lodato M, Tropea A, Cianci A. 2013. The role of cytoreductive surgery in advanced-stage ovarian cancer: a systematic review. Updates in Surgery 65:265–270.
   PubMedGoogle Scholar
• Vitale SG, Sapia F, Rapisarda AMC, Valenti G, Santangelo F, Rossetti D, et al. 2017. Hysteroscopic morcellation of submucous myomas: a systematic review. BioMed Research International 2017:6848250.
   PubMed Web of Science ®Google Scholar
• Vitale SG, Valenti G, Rapisarda AMC, Calì I, Marilli I, Zigarelli M, et al. 2016. P16INK4a as a progression/regression tumour marker in LSIL cervix lesions: our clinical experience. European Journal of Gynaecological Oncology 37:685–688.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. 2009. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. European Journal of Obstetrics & Gynecology and Reproductive Biology 144:163–167.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Derchain SF, Pitta DR, De Angelo Andrade LAL, Sarian LO. 2016. Comparing the Copenhagen Index (CPH-I) and risk of ovarian malignancy algorithm (ROMA): two equivalent ways to differentiate malignant from benign ovarian tumors before surgery? Gynecologic Oncology 140:481–485.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chan DW. 2010. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiology Biomarkers & Prevention 19:2995–2999.
   PubMed Web of Science ®Google Scholar